1
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
13132
Neoplasms
10477
Carcinoma, Non-Small-Cell Lung
6870
Prostatic Neoplasms
6268
Colorectal Neoplasms
5945
Lung Neoplasms
5102
Multiple Myeloma
3576
Pancreatic Neoplasms
3561
Leukemia, Myeloid, Acute
3510
Neoplasm Metastasis
3507
Carcinoma, Hepatocellular
3271
Ovarian Neoplasms
3168
Melanoma
3139
Stomach Neoplasms
3056
Lymphoma
2982
Head and Neck Neoplasms
2603
Recurrence
2556
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2499
Leukemia
2362
Colonic Neoplasms
2327
Brain Neoplasms
2310
Lymphoma, Non-Hodgkin
2268
Rectal Neoplasms
2191
Uterine Cervical Neoplasms
2191
Glioblastoma
2014
Leukemia, Lymphocytic, Chronic, B-Cell
1992
Carcinoma, Renal Cell
1913
Squamous Cell Carcinoma of Head and Neck
1880
Lymphoma, Follicular
1847
Esophageal Neoplasms
1800
Interventions
osimertinib
1
Gefitinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
×
Clear all
NCT02296125
2026-04-21
FLAURA
AstraZeneca
Phase 3
Completed
674 enrolled
21 charts
1 FDA